InvestorsHub Logo
Followers 23
Posts 2403
Boards Moderated 0
Alias Born 03/15/2007

Re: Couch post# 216861

Friday, 04/24/2015 5:37:34 PM

Friday, April 24, 2015 5:37:34 PM

Post# of 346365
FYI

About CheckMate -057

CheckMate -057 is a Phase III, open-label, randomized study of Opdivo versus docetaxel in previously treated patients with advanced or metastatic non-squamous NSCLC. The trial randomized 582 patients to receive either nivolumab 3 mg/kg intravenously every two weeks or docetaxel 75 mg/m2 intravenously every three weeks. The primary endpoint is overall survival. Secondary endpoints include objective response rate and progression free survival.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News